Biomedical, Clinical & Life Sciences

No Applicants // Limit: 1 // Tickets Available: 1 

 Multiple applications from an organization are not allowed. 

This notice announces the opportunity to apply for funding under the Maternal Health Training and Resource Center (MHTRC) program. The purpose of this program is to support MCHB’s maternal health recipients, with a primary focus on the State Maternal Health Innovation (State MHI) program, to improve maternal health and to respond to the needs of populations impacted by maternal mortality and severe maternal morbidity (SMM). The MHTRC will also provide limited support to MCHB’s maternal health recipients with the implementation of maternal health projects, innovations, and initiatives in their respective states, where funds are available.

The goals of the MHTRC are to improve maternal health by:

• Providing tailored technical assistance (TA), capacity-building assistance (CBA), and evaluation support services to recipients of MCHB’s maternal health programs to aid awardees in addressing the needs of maternal health for populations disproportionately impacted by maternal mortality and severe maternal morbidity (SMM).

• Establishing a national resource center that provides evidence-based strategies and guidance to improve maternal health, reduce maternal mortality and SMM, and advance health equity at the individual, interpersonal, community, and societal levels.

We estimate approximately $3,000,000 to be available annually to fund one recipient. You may apply for a ceiling amount of up to $3,000,000 annually (reflecting direct and indirect costs). The period of performance is September 30, 2024, through September 29, 2029 (5 years).

No Applicants   //  Limit: 1 // Tickets Available: 1 

Only one application per institution (normally identified by having a unique entity identifier (UEI) or NIH IPF number) is allowed.

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH.  The overarching goal of this R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation’s biomedical, behavioral and clinical research needs.

To accomplish the stated over-arching goal, this NOFO will support educational activities with a primary focus on:

• Courses for Skills Development

This R25 program will support the development and implementation of short courses to prepare nurse scientists, and scientists in aligned fields, to conduct firearm injury prevention research in support of the NINR Strategic Plan (https://www.ninr.nih.gov/aboutninr/ninr-mission-and-strategic-plan). Applications for courses that build on the existing knowledge, approaches, methods, and techniques related to injury prevention to advance research specifically in the area of firearm injury are encouraged. Proposed courses should include content related to inequities in firearm injuries (e.g., race, ethnicity, socioeconomic position, gender, geography, and their intersections) and research at the individual, community, institutional, and structural levels.

This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn.

Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Budgets are limited to $200,000 direct costs per year and need to reflect the actual needs of the proposed project.

The scope of the proposed project should determine the project period. The maximum project period is three (3) years

No Applicants // Limit: 1 // Tickets Available: 1 

The purpose of this notice of funding opportunity (NOFO) is to support enhanced surveillance and applied research for influenza virus or other respiratory infections in humans and animals in China. This support aims to better define the global risk and to build the evidence for prevention and control of novel and seasonal avian and non-avian seasonal influenza viruses and other respiratory diseases in China. The scope of research performed will include, but will not be limited to, activities such as estimating the burden and cost of illness for groups at high risk for severe disease; monitoring vaccine uptake and efficacy; promoting vaccine programs for groups at high risk for severe influenza complications; and conducting surveillance for detection and control of novel and seasonal influenza viruses and other respiratory pathogens. Research activities for the prevention and control of novel and seasonal influenza viruses and other respiratory pathogens and pandemic preparedness activities will be aimed at preventing and controlling the spread and transmission within China and potentially to other countries, including the United States. Continued monitoring, detection, and reporting of these influenza viruses and other respiratory pathogens in China will advance global health efforts. These activities will assist to inform global health infection control policies and prevent and control seasonal epidemic and pandemic influenza in countries around the world. This NOFO provides an opportunity to conduct research in these important areas.

No Applicants  // Limit: 1 // Tickets Available: 1 

These grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas. Applicants must have completed two years of their fellowship or not more than two years as a junior faculty instructor or assistant professor at the start of the award period. These grants encourage and cultivate the best and brightest researchers of the future.

Grant Criteria and Eligibility:

• The probability of an advance in prevention, diagnosis or treatment for the near-term
• The novelty of the concept and strategy
• The clarity of presentation
• The overall plan for bringing the research findings to clinical application
• Experience, background, and qualifications of the investigators
• Adequacy of resources and environment (facilities, patients, etc.)
• PCRF only funds non-profit institutions and they must be located in the US.
• PCRF does not have citizenship requirements for our investigators. However, the Principal Investigator needs to be employed by a non-profit U.S. institution that has an affiliation with a hospital.
• Basic Science Research and Translational Grants require the applicant to be a PhD and/or MD.
• Emerging Investigator applicants must have completed two years of their fellowship, or not more than two years as a junior faculty instructor or assistant professor at the start of the award period.

No Applicants // Limit: 1 // Tickets Available: 1 

These grants fund new research protocols and therapies that hold promise for improved outcomes and accelerates cures from the laboratory bench to the bedside of children and teens with high- risk cancers. This Grant is given to single or multi-institutional programs that involve open, cancer clinical trials or consortia, and implement new approaches to therapy. Applicants must be a PhD and/or MD.

Grant Criteria and Eligibility:

• The probability of an advance in prevention, diagnosis or treatment for the near-term
• The novelty of the concept and strategy
• The clarity of presentation
• The overall plan for bringing the research findings to clinical application
• Experience, background, and qualifications of the investigators
• Adequacy of resources and environment (facilities, patients, etc.)
• PCRF only funds non-profit institutions and they must be located in the US.
• PCRF does not have citizenship requirements for our investigators. However, the Principal Investigator needs to be employed by a non-profit U.S. institution that has an affiliation with a hospital.
• Basic Science Research and Translational Grants require the applicant to be a PhD and/or MD.
• Emerging Investigator applicants must have completed two years of their fellowship, or not more than two years as a junior faculty instructor or assistant professor at the start of the award period.

No Applicants  //  Limit: 1 // Tickets Available: 1 

These grants are designed to support Post-Doctoral Fellowships and Clinical Investigator training for emerging pediatric cancer researchers to pursue exciting research ideas. Applicants must have completed two years of their fellowship or not more than two years as a junior faculty instructor or assistant professor at the start of the award period. These grants encourage and cultivate the best and brightest researchers of the future.

Grant Criteria and Eligibility:

• The probability of an advance in prevention, diagnosis or treatment for the near-term
• The novelty of the concept and strategy
• The clarity of presentation
• The overall plan for bringing the research findings to clinical application
• Experience, background, and qualifications of the investigators
• Adequacy of resources and environment (facilities, patients, etc.)
• PCRF only funds non-profit institutions and they must be located in the US.
• PCRF does not have citizenship requirements for our investigators. However, the Principal Investigator needs to be employed by a non-profit U.S. institution that has an affiliation with a hospital.
• Basic Science Research and Translational Grants require the applicant to be a PhD and/or MD.
• Emerging Investigator applicants must have completed two years of their fellowship, or not more than two years as a junior faculty instructor or assistant professor at the start of the award period.

Limit: 2* // Tickets Available: 0

• Science & Engineering Track - P. Carini (Environmental Sciences)
• Medical Research Track - M. Cai (Chemistry & Biochemistry)

Please note the internal deadline has been extended to May 8, 2024. 

*UA may submit one concept paper in Physical Sciences and Engineering and one concept paper in Medical Sciences in this cycle.
The selected projects must participate in the concept counseling session with the W.M. Keck Foundation between July 1 and August 15 to determine if they can proceed to the Phase I submission.

The W.M. Keck Foundation Research Program uses a three-step process for this opportunity. The first step is a Concept paper. The Undergraduate Education program is currently not accepting concept papers. The next steps are by the foundation’s invitation. UArizona review criteria reflect previous interactions with the W.M. Keck Foundation. Proposals should focus on basic, fundamental science with broad applications. Grants range from $1 million to $5 million and are typically $2 million or less.

The proposed work should show a significant leap forward rather than an extension of existing work.  

To be considered by Keck, applicants must have a statement from a federal program officer expressing that the project is not a good fit due to risk (rather than technical or theoretical fit) or a decline from a federal program where the summary statement or individual reviews highlight the incredible novelty, but the high-risk nature that makes it difficult to fund at the federal level.

 

The Science and Engineering Research Program seeks to benefit humanity by supporting high-risk/high-impact projects that are distinctive and novel in their approach to intractable problems, push the edge of their field, or question the prevailing paradigm. Past grants have been awarded to support pioneering science and engineering research and the development of promising new technologies, instrumentation, or methodologies. 

The Medical Research Program seeks to advance the frontiers of medicine to benefit humanity by supporting high-risk/high-impact projects that are distinctive and novel in their approach to intractable problems, push the edge of their field, or question the prevailing paradigm. Past grants have supported pioneering biological research, basic research, and the development of promising new technologies. The Keck Foundation does NOT fund work that is clinical, applied, or translational; treatment trials; or research for the sole purpose of drug development. 

Both senior and early career investigators are encouraged to apply. Team approaches, including interdisciplinary teams, are encouraged.

No applicants // Limit: 1 // Tickets Available: 1

T. Kalin ( Phoenix Children’s Research Institute -Translational Research) Subaward 

Hyundai Hope On Wheels® [“HHOW”] is a 501(c)(3) non-profit organization that joined the fight against childhood cancer in 1998. The organization funds life-saving research and creates awareness for childhood cancer. Since its inception, HHOW has donated more than $225 million to fund pediatric cancer research. 

In 2024, the following categories of research grants for pediatric cancer are available per this RFP: 

• Hope Scholar Grant: $400,000 (two-year award), please see pages 4-5 for details. 

• Young Investigator Grant: $250,000 (two-year award), please see page 6 for details. 

Eligibility to apply for a Hope Scholar or Young Investigator Grant is limited to Children’s Oncology Group (“COG”) member institutions in the U.S. Each eligible institution may submit up to one application per grant category. Applicants will be notified by March 15, 2024, about grant awardees. If selected, the first funding installment is planned for release on December 31, 2024. Approved research projects may begin upon receipt of the initial grant award disbursement. If selected, material conditions for the institution that receives a grant are to agree to all terms and conditions of the grant agreement, and to agree to host a Hyundai Hope On Wheels handprint ceremony at its location or virtually during August or September of 2024. 

No applicants // Limit: 1 // Tickets Available: 1

Hyundai Hope On Wheels® [“HHOW”] is a 501(c)(3) non-profit organization that joined the fight against childhood cancer in 1998. The organization funds life-saving research and creates awareness for childhood cancer. Since its inception, HHOW has donated more than $225 million to fund pediatric cancer research. 

In 2024, the following categories of research grants for pediatric cancer are available per this RFP: 

• Hope Scholar Grant: $400,000 (two-year award), please see pages 4-5 for details. 

• Young Investigator Grant: $250,000 (two-year award), please see page 6 for details. 

Eligibility to apply for a Hope Scholar or Young Investigator Grant is limited to Children’s Oncology Group (“COG”) member institutions in the U.S. Each eligible institution may submit up to one application per grant category. Applicants will be notified by March 15, 2024, about grant awardees. If selected, the first funding installment is planned for release on December 31, 2024. Approved research projects may begin upon receipt of the initial grant award disbursement. If selected, material conditions for the institution that receives a grant are to agree to all terms and conditions of the grant agreement, and to agree to host a Hyundai Hope On Wheels handprint ceremony at its location or virtually during August or September of 2024. 

 Limit: 1 // K. Lutrick (Research, Family & Community Medicine) & K. Ellingson (Epidemiology and Biostatistics)

Only one application per institution (normally identified by having a unique entity identifier [UEI] number) is allowed. 

The purpose of this Notice of Funding Opportunity (NOFO) is to establish: 1) a multi-site community-based cohort study that would allow close monitoring of the burden of acute respiratory illness in the community, contributions of various respiratory viruses to this burden, and the impact of vaccination and other interventions on risk of infection and/or severe outcomes, and 2) a case-ascertained household transmission study (or multi-site study) that would support ongoing assessment of transmission dynamics of respiratory viruses of interest and factors (i.e., demographic, clinical, or household-level factors) that may impact transmission.

While hospital-based platforms are key to assessing frequency and risk factors for severe disease, community-based platforms are essential for understanding age-specific incidences of infection, risk factors for infection, socioeconomic burden of infections (such as days of work/school lost), and the clinical spectrum of illness. They are important for characterizing the immune response to infection or reinfection and long-term outcomes, and they are key to understanding the impact of individual- and household-level mitigation factors (including but not limited to vaccination) on all of these measures. This type of network may be especially useful for detecting changes in any of these factors when a new virus or viral variant begins circulating.

Case-ascertained household transmission studies are well-positioned to quickly and efficiently enable us to understand transmission dynamics of respiratory viruses (or sublineages/types of existing viruses that undergo frequent mutation, such as SARS-CoV-2 and influenza) and assess potential mitigation factors. These studies can also be valuable for characterizing viral shedding dynamics and infectiousness. These studies were key during the COVID-19 pandemic to understanding if changes in hospitalization rates were due to changes in transmissibility/infection rates versus changes in severity of illness. They are also great resources for assessing how history of vaccination or prior history of infection effect transmission to close contacts.

This NOFO would build on the lessons learned during the COVID-19 pandemic and establish a consolidated network of community cohorts to monitor a range of respiratory viruses among community members who develop symptoms of acute respiratory illness. Incorporation of multi-pathogen testing will allow us to better understand the relative contribution of various viruses to the overall community burden of respiratory disease now in the post-pandemic setting, and how the clinical spectrum of these illnesses compare, in a setting in which multiple new preventive products are becoming available. This would also support the establishment of a case-ascertained transmission study (or multi-site study) that would be able to assess SARS-CoV-2, Respiratory Syncytial Virus (RSV), and other prioritized respiratory viruses on an ongoing basis.

The combination of these studies will generate much greater visibility on risk factors for infection and the effectiveness of various interventions in reducing infections and viral transmission, factors that are relevant to reducing overall morbidity and mortality related to respiratory viruses. Should a new variant or virus arrive, this platform would be well positioned to further expand testing to better understand potential concerns like proportion symptomatic, timing of transmission, likelihood of asymptomatic transmission and other related questions. Such questions may be key to developing public health guidance should additional mitigation measures become necessary.